Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Metastasis | Research

A nomogram for predicting lateral lymph node metastasis in cN0 unifocal papillary thyroid microcarcinoma

Authors: Hui Huang, Siyuan Xu, Song Ni, Xiaolei Wang, Shaoyan Liu

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Identifying risk factors for occult lateral lymph node metastasis (LLNM) in papillary thyroid microcarcinoma (PTMC) can provide valuable insights into the necessity of lateral neck dissection (LND). The objective of this study was to develop a nomogram for predicting the probability of LLNM in patients with cN0 unifocal PTMC.

Methods

We conducted a retrospective analyzed a total of 4872 patients with cN0 unifocal PTMC who were treated at our center from January 2013 to June 2018. Logistic regression analysis was used to determine the risk factors for LLNM, and a nomogram was constructed based on these risk factors.

Results

The rate of LLNM was 3.2%. Tumors located in the upper lobe(odds ratio [OR] = 2.56, 95% confidence interval [CI] 1.80–3.62; p < 0.001) and size greater than 7 mm (OR = 2.59, 95% CI 1.85–3.62; p < 0.001) had a significantly higher risk of LLNM compared to tumors in the lower or middle lobe and size less than or equal to 7 mm. Tumors with extrathyroidal extension (ETE) had a significantly higher risk of LLNM (OR = 1.41, 95% CI 1.01–1.99; p = 0.044). The presence of three or more central lymph node metastases (CLNMs) (OR = 5.84, 95% CI 3.83–8.93; p < 0.001) or one or two CLNMs (OR = 2.91, 95% CI 1.93–4.42; p < 0.001) also increased the risk of LLNM compared to having no CLNMs. A nomogram incorporating these risk factors was developed, and the receiver operating characteristic (ROC) curve demonstrated an area under the curve (AUC) of 0.777, indicating a high degree of predictive accuracy.

Conclusion

Tumor location in the upper lobe, greater than 7 mm in size, ETE, and CLNMs, especially three or more, were independent risk factors for LLNM in cN0 unifocal PTMC. The nomogram based on these factors exhibited favorable predictive value and consistency.
Literature
1.
go back to reference Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 1989;63(5):908–11.CrossRefPubMed Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 1989;63(5):908–11.CrossRefPubMed
2.
go back to reference Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–48.CrossRefPubMedPubMedCentral Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–48.CrossRefPubMedPubMedCentral
3.
go back to reference Yu XM, Wan Y, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg. 2011;254(4):653–60.CrossRefPubMed Yu XM, Wan Y, Sippel RS, Chen H. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg. 2011;254(4):653–60.CrossRefPubMed
4.
go back to reference Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98(1):31–40.CrossRefPubMed Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98(1):31–40.CrossRefPubMed
5.
go back to reference Bramley MD, Harrison BJ. Papillary microcarcinoma of the thyroid gland. Br J Surg. 1996;83(12):1674–83.CrossRefPubMed Bramley MD, Harrison BJ. Papillary microcarcinoma of the thyroid gland. Br J Surg. 1996;83(12):1674–83.CrossRefPubMed
6.
go back to reference Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H, Takanashi Y. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237(3):399–407.CrossRefPubMedPubMedCentral Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H, Takanashi Y. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237(3):399–407.CrossRefPubMedPubMedCentral
7.
go back to reference Gülben K, Berberoğlu U, Celen O, Mersin HH. Incidental papillary microcarcinoma of the thyroid–factors affecting lymph node metastasis. Langenbecks Arch Surg. 2008;393(1):25–9.CrossRefPubMed Gülben K, Berberoğlu U, Celen O, Mersin HH. Incidental papillary microcarcinoma of the thyroid–factors affecting lymph node metastasis. Langenbecks Arch Surg. 2008;393(1):25–9.CrossRefPubMed
8.
go back to reference Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 american thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the american thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 american thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the american thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral
9.
go back to reference Wen X, Jin Q, Cen X, Qiu M, Wu Z. Clinicopathologic predictors of central lymph node metastases in clinical node-negative papillary thyroid microcarcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2022;20(1):106.CrossRefPubMedPubMedCentral Wen X, Jin Q, Cen X, Qiu M, Wu Z. Clinicopathologic predictors of central lymph node metastases in clinical node-negative papillary thyroid microcarcinoma: a systematic review and meta-analysis. World J Surg Oncol. 2022;20(1):106.CrossRefPubMedPubMedCentral
10.
go back to reference Chung YS, Kim JY, Bae JS, Song BJ, Kim JS, Jeon HM, Jeong SS, Kim EK, Park WC. Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. Thyroid. 2009;19(3):241–6.CrossRefPubMed Chung YS, Kim JY, Bae JS, Song BJ, Kim JS, Jeon HM, Jeong SS, Kim EK, Park WC. Lateral lymph node metastasis in papillary thyroid carcinoma: results of therapeutic lymph node dissection. Thyroid. 2009;19(3):241–6.CrossRefPubMed
11.
go back to reference So YK, Son YI, Hong SD, Seo MY, Baek CH, Jeong HS, Chung MK. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery. 2010;148(3):526–31.CrossRefPubMed So YK, Son YI, Hong SD, Seo MY, Baek CH, Jeong HS, Chung MK. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. Surgery. 2010;148(3):526–31.CrossRefPubMed
12.
go back to reference Parvathareddy SK, Siraj AK, Annaiyappanaidu P, Siraj N, Al-Sobhi SS, Al-Dayel F, Al-Kuraya KS. Risk factors for cervical lymph Node Metastasis in Middle Eastern Papillary thyroid Microcarcinoma. J Clin Med. 2022;11(15):4613.CrossRefPubMedPubMedCentral Parvathareddy SK, Siraj AK, Annaiyappanaidu P, Siraj N, Al-Sobhi SS, Al-Dayel F, Al-Kuraya KS. Risk factors for cervical lymph Node Metastasis in Middle Eastern Papillary thyroid Microcarcinoma. J Clin Med. 2022;11(15):4613.CrossRefPubMedPubMedCentral
13.
go back to reference Pisanu A, Reccia I, Nardello O, Uccheddu A. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World J Surg. 2009;33(3):460–8.CrossRefPubMed Pisanu A, Reccia I, Nardello O, Uccheddu A. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors. World J Surg. 2009;33(3):460–8.CrossRefPubMed
14.
go back to reference Siddiqui S, White MG, Antic T, Grogan RH, Angelos P, Kaplan EL, Cipriani NA. Clinical and pathologic predictors of Lymph Node Metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid. 2016;26(6):807–15.CrossRefPubMed Siddiqui S, White MG, Antic T, Grogan RH, Angelos P, Kaplan EL, Cipriani NA. Clinical and pathologic predictors of Lymph Node Metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid. 2016;26(6):807–15.CrossRefPubMed
15.
go back to reference Kim E, Park JS, Son KR, Kim JH, Jeon SJ, Na DG. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid. 2008;18(4):411–8.CrossRefPubMed Kim E, Park JS, Son KR, Kim JH, Jeon SJ, Na DG. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid. 2008;18(4):411–8.CrossRefPubMed
16.
go back to reference Amin MB, Edge SB, Greene FL. AJCC cancer staging manual. 8th ed. Chicago, il: Springer; 2017.CrossRef Amin MB, Edge SB, Greene FL. AJCC cancer staging manual. 8th ed. Chicago, il: Springer; 2017.CrossRef
17.
go back to reference Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, Kim JS. Predictive factors for Lymph Node Metastasis in Papillary thyroid Microcarcinoma. Ann Surg Oncol. 2016;23(9):2866–73.CrossRefPubMed Kim SK, Park I, Woo JW, Lee JH, Choe JH, Kim JH, Kim JS. Predictive factors for Lymph Node Metastasis in Papillary thyroid Microcarcinoma. Ann Surg Oncol. 2016;23(9):2866–73.CrossRefPubMed
18.
go back to reference Zhang L, Wei WJ, Ji QH, Zhu YX, Wang ZY, Wang Y, Huang CP, Shen Q, Li DS, Wu Y. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2012;97(4):1250–7.CrossRefPubMed Zhang L, Wei WJ, Ji QH, Zhu YX, Wang ZY, Wang Y, Huang CP, Shen Q, Li DS, Wu Y. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients. J Clin Endocrinol Metab. 2012;97(4):1250–7.CrossRefPubMed
19.
go back to reference Das R, Rahman T, Das AK, Das K, Das A, Kakati K, Das R. Pattern of nodal metastasis in relation to size of the primary Tumour in Well-Differentiated thyroid carcinoma. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl 2):2435–9.CrossRefPubMed Das R, Rahman T, Das AK, Das K, Das A, Kakati K, Das R. Pattern of nodal metastasis in relation to size of the primary Tumour in Well-Differentiated thyroid carcinoma. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl 2):2435–9.CrossRefPubMed
20.
go back to reference Lim YS, Lee JC, Lee YS, Lee BJ, Wang SG, Son SM, Kim IJ. Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery. 2011;150(1):116–21.CrossRefPubMed Lim YS, Lee JC, Lee YS, Lee BJ, Wang SG, Son SM, Kim IJ. Lateral cervical lymph node metastases from papillary thyroid carcinoma: predictive factors of nodal metastasis. Surgery. 2011;150(1):116–21.CrossRefPubMed
21.
go back to reference Back K, Kim JS, Kim JH, Choe JH. Superior located papillary thyroid Microcarcinoma is a risk factor for lateral lymph node metastasis. Ann Surg Oncol. 2019;26(12):3992–4001.CrossRefPubMed Back K, Kim JS, Kim JH, Choe JH. Superior located papillary thyroid Microcarcinoma is a risk factor for lateral lymph node metastasis. Ann Surg Oncol. 2019;26(12):3992–4001.CrossRefPubMed
22.
go back to reference Ducoudray R, Trésallet C, Godiris-Petit G, Tissier F, Leenhardt L, Menegaux F. Prophylactic lymph node dissection in papillary thyroid carcinoma: is there a place for lateral neck dissection? World J Surg. 2013;37(7):1584–91.CrossRefPubMed Ducoudray R, Trésallet C, Godiris-Petit G, Tissier F, Leenhardt L, Menegaux F. Prophylactic lymph node dissection in papillary thyroid carcinoma: is there a place for lateral neck dissection? World J Surg. 2013;37(7):1584–91.CrossRefPubMed
23.
go back to reference Lee YS, Shin SC, Lim YS, Lee JC, Wang SG, Son SM, Kim IJ, Lee BJ. Tumor location-dependent skip lateral cervical lymph node metastasis in papillary thyroid cancer. Head Neck. 2014;36(6):887–91.CrossRefPubMed Lee YS, Shin SC, Lim YS, Lee JC, Wang SG, Son SM, Kim IJ, Lee BJ. Tumor location-dependent skip lateral cervical lymph node metastasis in papillary thyroid cancer. Head Neck. 2014;36(6):887–91.CrossRefPubMed
24.
go back to reference Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg. 2004;28(11):1115–21.CrossRefPubMed Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg. 2004;28(11):1115–21.CrossRefPubMed
25.
go back to reference Kwak JY, Kim EK, Kim MJ, Son EJ, Chung WY, Park CS, Nam KH. Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Ann Surg Oncol. 2009;16(5):1348–55.CrossRefPubMed Kwak JY, Kim EK, Kim MJ, Son EJ, Chung WY, Park CS, Nam KH. Papillary microcarcinoma of the thyroid: predicting factors of lateral neck node metastasis. Ann Surg Oncol. 2009;16(5):1348–55.CrossRefPubMed
26.
go back to reference Wang D, Zhu J, Deng C, Yang Z, Hu D, Shu X, Yu P, Su X. Preoperative and pathological predictive factors of central lymph node metastasis in papillary thyroid microcarcinoma. Auris Nasus Larynx. 2022;49(4):690–6.CrossRefPubMed Wang D, Zhu J, Deng C, Yang Z, Hu D, Shu X, Yu P, Su X. Preoperative and pathological predictive factors of central lymph node metastasis in papillary thyroid microcarcinoma. Auris Nasus Larynx. 2022;49(4):690–6.CrossRefPubMed
27.
go back to reference Bohec H, Breuskin I, Hadoux J, Schlumberger M, Leboulleux S, Hartl DM. Occult Contralateral lateral lymph node metastases in unilateral N1b papillary thyroid carcinoma. World J Surg. 2019;43(3):818–23.CrossRefPubMed Bohec H, Breuskin I, Hadoux J, Schlumberger M, Leboulleux S, Hartl DM. Occult Contralateral lateral lymph node metastases in unilateral N1b papillary thyroid carcinoma. World J Surg. 2019;43(3):818–23.CrossRefPubMed
28.
go back to reference Giordano D, Frasoldati A, Kasperbauer JL, Gabrielli E, Pernice C, Zini M, Pedroni C, Cavuto S, Barbieri V. Lateral neck recurrence from papillary thyroid carcinoma: predictive factors and prognostic significance. Laryngoscope. 2015;125(9):2226–31.CrossRefPubMed Giordano D, Frasoldati A, Kasperbauer JL, Gabrielli E, Pernice C, Zini M, Pedroni C, Cavuto S, Barbieri V. Lateral neck recurrence from papillary thyroid carcinoma: predictive factors and prognostic significance. Laryngoscope. 2015;125(9):2226–31.CrossRefPubMed
29.
go back to reference Xu S, Huang H, Huang Y, Wang X, Xu Z, Liu S, Liu J. Risk stratification of lateral neck recurrence for patients with pN1a papillary thyroid cancer. BMC Cancer. 2022;22(1):1246.CrossRefPubMedPubMedCentral Xu S, Huang H, Huang Y, Wang X, Xu Z, Liu S, Liu J. Risk stratification of lateral neck recurrence for patients with pN1a papillary thyroid cancer. BMC Cancer. 2022;22(1):1246.CrossRefPubMedPubMedCentral
Metadata
Title
A nomogram for predicting lateral lymph node metastasis in cN0 unifocal papillary thyroid microcarcinoma
Authors
Hui Huang
Siyuan Xu
Song Ni
Xiaolei Wang
Shaoyan Liu
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Metastasis
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11219-0

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine